subscribeSubscribe
Synthon Pharms Generic Palbociclib Receives Approval in US

Synthon Pharms Generic Palbociclib Receives Approval in US
FDA
05 Jun 2024
Share Share
Roche’s PI3K inhibitor wins FDA priority review for breast cancer

Roche’s PI3K inhibitor wins FDA priority review for breast cancer
Phalguni Deswal PHARMACEUTICAL TECHNOLOGY
30 May 2024
Share Share
Arvinas & Pfizer announce updated clinical data from Ph1b Trial of Vepdegestrant

Arvinas & Pfizer announce updated clinical data from Ph1b Trial of Vepdegestrant
INDINPHARMAPOST
18 May 2024
Share Share
Pfizer, Arvinas’ breast cancer drug combo keeps momentum after Phase 1b update

Pfizer, Arvinas’ breast cancer drug combo keeps momentum after Phase 1b update
ENDPTS
16 May 2024
Share Share
AbbVie`s Humira, J&J`s Darzalex top ICER`s annual price-hike list

AbbVie`s Humira, J&J`s Darzalex top ICER`s annual price-hike list
Zoey Becker FIERCE PHARMA
11 Dec 2023
Share Share
Roche`s inavolisib combo cuts breast cancer progression by 57%

Roche`s inavolisib combo cuts breast cancer progression by 57%
PRESS RELEASE
09 Dec 2023
Share Share
Olema Announces Palazestrant Demonstrates Combinability with CDK4/6 Inhibitors

Olema Announces Palazestrant Demonstrates Combinability with CDK4/6 Inhibitors
GLOBENEWSWIRE
05 Dec 2023
Share Share
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
GLOBENEWSWIRE
30 May 2023
Share Share
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
GLOBENEWSWIRE
11 May 2023
Share Share
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation

Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
REUTERS
14 Mar 2023
Share Share